Monoclonal gammopathy of unknown significance (MGUS) & importance of regularly monitoring patients

Irene Ghobrial, MD, of Dana-Farber Cancer Institute, Boston, MA, discusses monoclonal gammopathy of unknown significance (MGUS). There are still questions around how to follow up patients with MGUS and whether these patients should be followed up regularly or not. Watch video here.

Recent Posts

See All

Honoring a decade of Standing Up To Cancer

On September 7, Stand Up To Cancer’s (SU2C) telecast shared inspiring stories of hope, perseverance, and groundbreaking cancer research to a worldwide audience. +read more

DFCI Logo Lens Stacked PNG_edited.png

© 2018 Dana-Farber Cancer Institute |  Terms of Use  |   Privacy Policy